SCHEMBL7218318

SCHEMBL7218318

CCN(CC)CCn1cc2c(n1)-c1c(C(=O)Nc3ccn(C)n3)c[nH]c1CCC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
GRM5 P41594 2/20 0.34
MAPK7 Q13164 1/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CCNC P24863 1/20 0.32
CDK8 P49336 1/20 0.32
CDK19 Q9BWU1 1/20 0.32
KMT2A Q03164 1/20 0.32
TLR8 Q9NR97 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6834410 0.88 NPC1 (0.36) LMNANPC1RAB9ACHRM2CHRM4
SCHEMBL6309664 0.83 MAPT (0.34) LMNATP53MAPTKDM4EALDH1A1
SCHEMBL6830901 0.82 SMN1; SMN2 (0.37) LMNATP53MAPTNPC1RAB9A
SCHEMBL7218239 0.82 GCK (0.33) LMNANPC1RAB9ACHRM2CHRM4
SCHEMBL6305849 0.80 MAPT (0.36) LMNATP53MAPTNPC1RAB9A
SCHEMBL7223491 0.78 GCK (0.32) KDM4EALDH1A1
SCHEMBL7216152 0.77 PDE4B (0.42) NPC1RAB9ACHRM2CHRM4CHRM1
SCHEMBL7216346 0.74 NPC1 (0.41) LMNANPC1RAB9ACHRM2CHRM4
SCHEMBL7221974 0.73 GRM4 (0.43) LMNANPC1RAB9ACHRM2CHRM4
SCHEMBL6834487 0.72 GAA (0.43) TP53NPC1RAB9AGRM5KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6653471-B2 Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction NEUROGEN CORPORATION 2003-11-25 US disclosed